Myasthenia gravis. Pathogenesis and current concepts in management

Area of Science:

• Neurology
• Immunology
• Autoimmune Disorders

Background:

• Myasthenia gravis is an autoimmune disorder characterized by impaired neuromuscular transmission due to autoantibodies targeting the acetylcholine receptor (AChR).
• Evidence suggests multiple forms of myasthenia gravis exist, potentially with distinct genetic susceptibilities.
• The exact etiology remains unknown, but thymic abnormalities and positive responses to thymectomy suggest a role for the thymus.

Purpose of the Study:

• To review the current understanding and treatment strategies for myasthenia gravis.
• To highlight the role of the thymus and thymectomy in managing myasthenia gravis.
• To discuss various therapeutic options, including symptomatic treatments, immunosuppression, and potential future therapies.

Main Methods:

• Review of existing literature on myasthenia gravis.
• Analysis of treatment outcomes for thymectomy, anticholinesterase drugs, immunosuppressants, and plasma exchange.
• Discussion of the immunological basis and potential future therapeutic targets.

Main Results:

• Thymectomy is beneficial in over two-thirds of patients and indicated for most, leading to remission in about one-third.
• Most patients require symptomatic treatment with anticholinesterase drugs; over-dosage can worsen weakness.
• Immunosuppression (corticosteroids, azathioprine) is effective for non-responders or unsuitable surgical candidates. Plasma exchange offers temporary relief.
• Future therapies may involve specific immunotherapy, such as anti-idiotype antibodies.

Conclusions:

• Thymectomy is a key treatment for myasthenia gravis, often combined with symptomatic or immunosuppressive therapies.
• Management requires careful consideration of individual patient factors and treatment responses.
• Ongoing research into specific immunotherapies holds promise for future treatment advancements.